Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pavli Demian

Pain Medicine Somerset, NJ Doctor of Osteopathy

NPI 1841622453 CMS profile 4219513

2 Worlds Fair Dr, Ste 103, Somerset, NJ 08873

Open in the dashboard

General payments

$65,225

662 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pavli Demian of Somerset, NJ is reported in the CMS Open Payments database as having received $65,225 across 662 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,692 40
2024 General $19,377 52
2023 General $13,594 62
2022 General $7,233 130
2021 General $6,115 151
2020 General $1,342 93
2019 General $4,873 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pavli Demian
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Pavli Demian were reported at $12,692. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Pavli Demian Pain Medicine median Middle half National median
2019 $4,873 $409 $115–$1,311 $163
2020 $1,342 $214 $66–$666 $114
2021 $6,115 $299 $84–$899 $132
2022 $7,233 $335 $103–$1,149 $149
2023 $13,594 $376 $114–$1,228 $160
2024 $19,377 $387 $115–$1,173 $164
2025 $12,692 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $58,572 480 payments
  2. Vertiflex, Inc. $2,558 13 payments
  3. Medtronic USA, Inc. $1,104 25 payments
  4. Scilex Pharmaceuticals Inc. $388 27 payments
  5. Stryker Corporation $278 4 payments
  6. Biodelivery Sciences International, Inc. $276 22 payments
  7. NuVasive, Inc. $246 2 payments
  8. Boston Scientific Corporation $236 13 payments
  9. Vertos Medical, Inc. $179 2 payments
  10. TerSera Therapeutics LLC $174 12 payments
  11. Other $1,214 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,534 25 payments
  2. Food and Beverage $12,353 590 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,385 13 payments
  4. Travel and Lodging $6,514 28 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $4,125 3 payments
  6. Education $315 3 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $31,077 106 payments
  2. PROCLAIM Structural Heart $9,973 18 payments
  3. Proclaim IPG $4,950 72 payments
  4. PRODIGY Neuromodulation $4,794 4 payments
  5. Superion ISS $2,558 13 payments
  6. PROCLAIM Neuromodulation $2,034 30 payments
  7. PRODIGY Structural Heart $1,547 1 payment
  8. INTELLIS $981 18 payments
  9. PROCLAIM Neuromodulation $845 18 payments
  10. Proclaim Family of SCS IPGs $662 65 payments
  11. Other $6,575 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

401

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,539

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

7.5%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 126 $1,310
Celecoxib Generic 76 $1,139
Cephalexin Generic 30 $898
Methylprednisolone Generic 78 $517
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 30 $355
Tramadol Hcl Generic 33 $197
Pregabalin Generic 13 $91
Meloxicam Generic 15 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$228,038

Of which drugs: $16,720

Medicare patients

442

Average age 75

Services billed

7,069

265 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 34%
Depression 23%
Chronic kidney disease 20%
Cancer 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 11 960 $5,029
Injection, methylprednisolone acetate, 1 mg J1010 Office 74 3,520 $362
Injection, methylprednisolone acetate, 40 mg J1030 Office 26 36 $166

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

662 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record